98827-44-2

Basic information

• Product Name: METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE
• Synonyms: METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE;Albb-008913;methy1 4-hydroxy-2H-thieno[2,3 -e]-1,2-thiazine-3-carboxylate-1, 1-dioxide;methyl 4-hydroxy-1,1-dioxo-2H-thieno[2,3-e]thiazine-3-carboxylate
• CAS NO: 98827-44-2
• Molecular Formula: C₈H₇NO₅S₂
• Molecular Weight: 261.27
• EINECS: 1533716-785-6
• Mol File: 98827-44-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 464.2 °C at 760 mmHg
• Flash Point: 234.6 °C
• Appearance: /
• Density: 1.716
• Vapor Pressure: 2.04E-09mmHg at 25°C
• Refractive Index: 1.667
• CAS DataBase Reference: METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE(98827-44-2)
• EPA Substance Registry System: METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE(98827-44-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 98827-44-2(Hazardous Substances Data)

Usage

General Description

Methyl 4-hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-carboxylate-1,1-dioxide is a chemical compound with a complex molecular structure. It contains a methyl group, a hydroxy group, and a carboxylate group, as well as a thieno-thiazine ring system. The presence of a 1,1-dioxide moiety further adds to the uniqueness of this compound. It has potential applications in the pharmaceutical and agrochemical industries, as well as in organic synthesis and material science. However, due to its complex structure, it requires careful handling and thorough understanding of its properties and reactivity.

InChI:InChI=1/C8H7NO5S2/c1-14-8(11)5-6(10)7-4(2-3-15-7)16(12,13)9-5/h2-3,9-10H,1H3

Upstream product

• 106820-63-7 methyl 3-<<<(methoxcarbonyl)methyl>amino>sulfonyl>-2-thiophenecarboxylate 
• 1028285-17-7 (1,1,3-Trioxo-1,3-dihydro-1λ⁶-thieno[2,3-d]isothiazol-2-yl)-acetic acid methyl ester 
• 59337-91-6 3-chlorosulfonyl-thiophene-2-carboxylic acid chloride 
• 59337-92-7 2-(carbomethoxy)thiophene-3-sulfonyl chloride 
• 59337-89-2 3-chlorothiophene-2-carboxylic acid 
• 59337-94-9 2,3-dihydro-3-oxo-thieno<2,3-d>isothiazole-1,1-dioxide 

Downstream Products

• 59804-37-4 tenoxicam 
• 59804-25-0 4-hydroxy-3-methoxycarbonyl-2-methyl-2H-thieno[2,3-e]-1,2-thiazine,1,1-dioxide 
• 106820-69-3 4-Hydroxy-2-(4-methoxy-benzyl)-1,1-dioxo-1,2-dihydro-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxylic acid pyridin-2-ylamide 
• 59804-42-1 N-(3-chlorophenyl)-4-hydroxy-2-methyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide 
• 59804-40-9 4-hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1λ⁶-thieno[2,3-e][1,2]thiazine-3-carboxylic acid 4-hydroxy-anilide 
• 59804-41-0 4-hydroxy-N-(3-methylphenyl)-2-methyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide 
• 59804-36-3 4-hydroxy-2-methyl-N-phenyl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide 
• 106820-61-5 methyl 4-hydroxy-2-<(4-methoxyphenyl)methyl>-2H-thieno<2,3-e>-1,2-thiazine-3-carboxylate 1,1-dioxide 

Relevant articles and documents

5-aminothiazole non-steroidal anti-inflammatory compound as well as preparation method and application thereof

The invention discloses a 5-aminothiazole non-steroidal anti-inflammatory compound. The compound which is efficient, low in toxicity and small in side effect is prepared from an ester intermediate containing a thiazine ring and a 5-aminothiazole derivative through a transesterification reaction. The preparation method of the compound is simple, the compound has the active groups of the existing non-steroidal anti-inflammatory medicine; meanwhile, the special change of the nitrogen atom position is also designed; compared with the existing non-steroidal anti-inflammatory medicines, the compoundhas better anti-inflammatory and analgesic effects, particularly has good curative effects on arthritis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, soft tissue inflammation and thelike, has small toxic and side effects on human bodies, and has a very wide market prospect.

Synthesis method of tenoxicam

The invention relates to a synthesis method of tenoxicam. The synthesis method takes 3-[[N-(methoxycarbonyl)methyl]sulfonyl]-2-thiophenecarboxylate as a starting raw material and comprises the following steps: carrying out cyclization on the starting raw material to obtain a 4-hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-methyl formate1,1-dioxide intermediate; carrying out reaction on the 4-hydroxy-2H-thieno[2,3-e]-1,2-thiazine-3-methyl formate1,1-dioxide intermediate, dimethyl carbonate and 2-aminopyridine through a one-pot method to prepare the tenoxicam. A synthesis route is as follows: the synthesis route is shown in the description. The synthesis method provided by the invention has the advantages that the synthesis method has a short route and no hazardous process and is green and environmentally friendly; a final aminolysis step is avoided and raw materials react completely; the yield is more than or equal to 80 percent; the raw materials and a product are not easy to carbonize and decompose and side reaction is reduced; the product is easy to purify and the purity of the product can reach 99.85 percent; the synthesis method is a synthesis process capable of realizing industrialized production.

Analogues and Derivatives of Tenoxicam. 1. Synthesis and Antiinflammatory Activity of Analogues with Different Residues on the Ring Nitrogen and the Amide Nitrogen

The synthesis of tenoxicam, 4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno-1,2-thiazine-3-carboxamide 1,1-dioxide (1e), and of the analogues with various residues on the ring nitrogen and the amide nitrogen is described.This new class of "oxicams" has pronounced antiinflammatory and analgesic properties.The very specific structure-activity relationship of isomeric and isosteric groups at the amide nitrogen has been evaluated.The substituent in position 2 also has a great influence on the pharmacological properties.Tenoxicam is presently underrgoing clinical trials.